Thus, many data have shown that the NK-1R is a new potential target for the treatment of any type of tumor (both solid and non-solid), because it is known that NK-1R antagonists, via the NK-1R, induce apoptosis in cancer cells (Figure 1) [1,13,21,27,30,37,48,49]. Here, TACR1 is linked to cancer.